Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort study.
graft outcome
hyperparathyroidism
kidney transplantation
parathormone
tertiary hyperparathyroidism
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
05
2023
accepted:
20
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
We studied the association between parathormone (PTH) levels and long-term graft loss in RTx patients (RTx-p). We retrospectively evaluated 871 RTx-p, transplanted in our unit from Jan-2004 to Dec-2020 assessing renal function and mineral metabolism parameters at 1, 6, and 12 months after RTx. Graft loss and death with functioning graft during follow-up (FU, 8.3[5.4-11.4] years) were checked. At month-1, 79% had HPT, of which 63% with secondary HPT (SHPT) and 16% tertiary HPT (THPT); at month-6, HPT prevalence was 80% of which SHPT 64% and THPT 16%; at month-12 HPT prevalence was 77% of which SHPT 62% and THPT 15%. A strong significant correlation was found between HPT type, PTH levels and graft loss at every time point. Mean PTH exposure remained strongly and independently associated to long term graft loss (OR 3.1 [1.4-7.1], High PTH levels during 1st year of RTx seem to be associated with long term graft loss.
Identifiants
pubmed: 37636567
doi: 10.3389/fmed.2023.1221086
pmc: PMC10449540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1221086Informations de copyright
Copyright © 2023 Molinari, Regalia, Leoni, Campise, Cresseri, Cicero, Vettoretti, Nardelli, Brigatti, Favi, Messa, Castellano and Alfieri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor VP declared a past collaboration (abstract presented during the ERA-EDTA 2022 congress) with the author CA.
Références
Endocrine. 2015 Mar;48(2):709-11
pubmed: 24965230
Sci Rep. 2020 Feb 4;10(1):1795
pubmed: 32020002
J Am Soc Nephrol. 2005 Mar;16(3):763-73
pubmed: 15659562
Nephrol Dial Transplant. 2021 Nov 9;36(11):2130-2139
pubmed: 34383929
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):855-865
pubmed: 34060245
Ann Surg. 2015 Oct;262(4):653-9
pubmed: 26366545
Front Horm Res. 2019;51:91-108
pubmed: 30641516
Kidney Int Suppl. 2009 Aug;(113):S1-130
pubmed: 19644521
Transplantation. 2015 Feb;99(2):351-9
pubmed: 25594550
Langenbecks Arch Surg. 2015 Dec;400(8):907-27
pubmed: 26429790
Kidney Int. 1998 Nov;54(5):1704-13
pubmed: 9844148
Cell Metab. 2016 Feb 9;23(2):315-23
pubmed: 26669699
Surgery. 2018 May;163(5):1144-1150
pubmed: 29331397
Endocr J. 2011;58(10):827-33
pubmed: 21804261
Clin J Am Soc Nephrol. 2012 Jul;7(7):1155-62
pubmed: 22554719
Surgery. 2022 Jan;171(1):69-76
pubmed: 34266650
Kidney Int. 2018 Sep;94(3):491-501
pubmed: 29861059
Eur Arch Otorhinolaryngol. 2012 Jun;269(6):1565-76
pubmed: 22101574
Transplant Proc. 2012 Nov;44(9):2567-9
pubmed: 23146456
Clin Transplant. 2014 Feb;28(2):161-5
pubmed: 24329899
Kidney Int. 2016 Nov;90(5):985-996
pubmed: 27457912
J Am Soc Nephrol. 2011 May;22(5):956-66
pubmed: 21436289
Arthritis Res Ther. 2012 Mar 10;14(2):R56
pubmed: 22405053
Clin Exp Nephrol. 2022 Jul;26(7):613-629
pubmed: 35353283
BMC Nephrol. 2022 Jun 17;23(1):212
pubmed: 35710357
Front Med (Lausanne). 2022 Mar 10;9:821884
pubmed: 35360722
Nephrol Dial Transplant. 2007 Jun;22(6):1730-7
pubmed: 17371780
Clin Transplant. 2020 Nov;34(11):e14085
pubmed: 32949044
Nephrol Dial Transplant. 2004 May;19(5):1281-7
pubmed: 14993493
Clin Transplant. 2014 Apr;28(4):479-86
pubmed: 25649861
Transplantation. 2013 May 27;95(10):1211-7
pubmed: 23511243
Kidney Int. 2018 Sep;94(3):453-455
pubmed: 30143064